Neuromyelitis optica

Florence Pache; Brigitte Wildemann; Friedemann Paul; Sven Jarius

doi:10.1055/s-0042-124186

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr 2017; 85(02): 100-114
DOI: 10.1055/s-0042-124186

Fort- und Weiterbildung

Neuromyelitis optica

Florence Pache

¹NeuroCure Clinical Research Center und Klinisches und Experimentelles Forschungszentrum für Multiple Sklerose, Klinik für Neurologie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

,

Brigitte Wildemann

²AG Molekulare Neuroimmunologie, Neurologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

,

Friedemann Paul

¹NeuroCure Clinical Research Center und Klinisches und Experimentelles Forschungszentrum für Multiple Sklerose, Klinik für Neurologie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

³Experimental and Clinical Research Center, Max Delbrueck Centrum für Molekulare Medizin und Charité – Universitätsmedizin Berlin, Berlin, Deutschland

,

Sven Jarius

²AG Molekulare Neuroimmunologie, Neurologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

› Institutsangaben

Abstract

Zusammenfassung

Die Neuromyelitis optica (NMO) ist eine autoimmun vermittelte entzündliche Erkrankung des zentralen Nervensystems (ZNS), die insbesondere das Rückenmark und die Sehnerven betrifft. Neuropathologisch ist die NMO durch Antikörper- und Komplementablagerungen, Astrozytenverlust, nekrotische Veränderungen mit Infiltration neutrophiler und eosinophiler Granulozyten und sekundären Untergang von Oligodendrozyten und Neuronen gekennzeichnet. Bei der Abgrenzung gegenüber der klinisch ähnlichen, aber deutlich häufigeren Multiplen Sklerose (MS) hilft insbesondere der Nachweis von Autoantikörpern gegen Aquaporin-4 (AQP4-Ak, NMO-IgG), die im Serum von über 80 % der NMO-Patienten nachgewiesen werden können. Das Zielantigen des Autoantikörpers, das Wasserkanalprotein Aquaporin-4, wird in hoher Konzentration in den Astrozyten-Endfüßchen der Glia limitans interna und externa exprimiert und ist als wichtiger Bestandteil der Blut-Hirn-Schranke an der Aufrechterhaltung der Wasserhomöostase des ZNS beteiligt. Neben den beiden Indexmanifestationen Optikusneuritis und Myelitis kommen häufig auch Hirnstamm- und Dienzephalitiden vor. Als besonders charakteristisch gilt das Area-postrema-Syndrom, das durch entzündliche Läsionen in der dorsalen Medulla verursacht wird und durch unstillbaren Schluckauf und/oder unstillbares Erbrechen gekennzeichnet ist. Die klinischen Symptome der NMO treten zumeist schubförmig auf, selten verläuft die Erkrankung monophasisch. Die Behandlung akuter Schübe erfolgt mit hochdosierten intravenösen Steroiden und/oder Plasmapherese, zur Rezidivprophylaxe ist eine Therapie mit Immunsuppressiva oder B-Zell-depletierenden Therapien essentiell.

Abstract

Neuromyelitis optica (NMO) is an autoimmune disorder of the central nervous system (CNS) that predominantly affects the spinal cord and optic nerves. The neuropathologic hallmarks comprise deposits of antibodies and complement as well as loss of astrocytes, secondary degeneration of oligodendrocytes and neurons, and necrotic lesions with infiltration of neutrophilic and eosinophilic granulocytes. Pathognomonic serum autoantibodies against aquaporin-4 (AQP4-IgG, also termed NMO-IgG) are detectable in around 80 % of NMO patients and help to distinguish this rare entity from multiple sclerosis. The target antigen of NMO-IgG, the water channel protein AQP4, is ubiquitously expressed within the CNS and, as a component of the blood-brain barrier, highly concentrated in the endfeet of astrocytes. New international consensus criteria for NMO spectrum disorders, published in 2015, allow earlier diagnosis. Besides the two index manifestations, optic neuritis and transverse myelitis, involvement of the brainstem and diencephalon is relatively common in NMO. Inflammatory lesions of the area postrema typically cause intractable nausea and vomiting and/or hiccups. NMO mostly follows a relapsing course, especially in AQP4-IgG-positive cases. The treatment of acute exacerbations comprises intravenous methylprednisolone pulses and/or plasma exchange, and prevention of attacks requires long-term therapy with immunosuppressants and/or B-cell-depleting monoclonal antibodies.

Schlüsselwörter

Neuromyelitis optica - Autoimmunerkrankung - Neuromyelitis - Sehnerv - Aquaporin-4

Keywords

neuromyelitis optica - autoimmune disorder - myelitis - optic nerve - aquaporin-4

Volltext

Referenzen

Literatur
1 Trebst C. Jarius S. Berthele A. et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261: 1-16
2 Jarius S. Wildemann B. Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014; 176: 149-164
3 Jarius S. Ruprecht K. Wildemann B. et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012; 9: 14
4 Kim HJ. Paul F. Lana-Peixoto MA. Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84: 1165-1173
5 Wingerchuk DM. Banwell B. Bennett JL. et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189
6 Jarius S. Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013; 10: 8
7 Jacob A. Larner AJ. Clifford Allbutt (1836–1925). J Neurol 2013; 260: 346-347
8 Jarius S. Wildemann B. An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler Houndmills Basingstoke Engl 2011; 17: 1384-1386
9 Jarius S. Wildemann B. Devic’s disease before Devic: Bilateral optic neuritis and simultaneous myelitis in a young woman (1874). J Neurol Sci 2015; 358: 419-421
10 Jarius S. Wildemann B. The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol 2012; 259: 1354-1357
11 Jarius S. Wildemann B. “Noteomielite” accompanied by acute amaurosis (1844). An early case of neuromyelitis optica. J Neurol Sci 2012; 313: 182-184
12 Jarius S. Wildemann B. On the contribution of Thomas Clifford Allbutt, F. R. S., to the early history of neuromyelitis optica. J Neurol 2013; 260: 100-104
13 Jarius S. Wildemann B. “Spinal amaurosis” (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. J Neurol 2014; 261: 400-404
14 Jarius S. Wildemann B. An early British case of neuromyelitis optica (1850). BMJ 2012; 345: e6430
15 Wingerchuk DM. Hogancamp WF. O’Brien PC. et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107-1114
16 Weinshenker BG. Wingerchuk DM. Vukusic S. et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566-569
17 Zekeridou A. Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflammation 2015; 2: e110
18 Melamed E. Levy M. Waters PJ. et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflammation 2015; 2: e134
19 Waters P. Jarius S. Littleton E. et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65: 913-919
20 Jarius S. Franciotta D. Bergamaschi R. et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68: 1076-1077
21 Paul F. Jarius S. Aktas O. et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007; 4: e133
22 Metz I. Beißbarth T. Ellenberger D. et al. Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol Neuroinflammation 2016; 3: e204
23 Waters P. Reindl M. Saiz A. et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016; 87: 1005-1015
24 Wingerchuk DM. Lennon VA. Pittock SJ. et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489
25 Wingerchuk DM. Lennon VA. Lucchinetti CF. et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815
26 Kister I. Paul F. Pushing the boundaries of neuromyelitis optica: does antibody make the disease?. Neurology 2015; 85: 118-119
27 Paty DW. Oger JJ. Kastrukoff LF. et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180-185
28 Wildemann B. Jarius S. Paul F. Neuromyelitis optica. Aktuelle Neurol 2012; 39: 33-41
29 Flanagan EP. Cabre P. Weinshenker BG. et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016;
30 Pandit L. Asgari N. Apiwattanakul M. GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica. et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler Houndmills Basingstoke Engl 2015; 21: 845-853
31 Weinshenker BG. Wingerchuk DM. Nakashima I. et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006; 5: 110-111
32 Sepúlveda M. Armangué T. Sola-Valls N. et al. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflammation 2016; 3: e225
33 Wingerchuk DM. Pittock SJ. Lucchinetti CF. et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68: 603-605
34 Fujihara K. Nakashima I. Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?. Neurol Neuroimmunol Neuroinflammation 2014; 1: e38
35 Gelfand JM. Cotter J. Klingman J. et al. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflammation 2014; 1: e34
36 Krumbholz M. Hofstadt-van Oy U. Angstwurm K. et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol 2015; 262: 1379-1384
37 Borisow N. Kleiter I. Gahlen A. on behalf of NEMOS (Neuromyelitis Optica Study Group). et al. Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler J 2016; Im Internet: http://msj.sagepub.com/cgi/doi/10.1177/1352458516671203 Stand: 13.01.2017
38 Jarius S. Paul F. Franciotta D. et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler Houndmills Basingstoke Engl 2012; 18: 1135-1143
39 Leite MI. Coutinho E. Lana-Peixoto M. et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012; 78: 1601-1607
40 Jarius S. Jacobi C. de Seze J. et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler Houndmills Basingstoke Engl 2011; 17: 1067-1073
41 Popescu BFG. Lennon VA. Parisi JE. et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76: 1229-1237
42 Takahashi T. Miyazawa I. Misu T. et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 2008; 79: 1075-1078
43 Misu T. Fujihara K. Nakashima I. et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005; 65: 1479-1482
44 Apiwattanakul M. Popescu BF. Matiello M. et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010; 68: 757-761
45 Jarius S. Lauda F. Wildemann B. et al. Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol 2013; 260: 663-664
46 Kremer L. Mealy M. Jacob A. et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 2014; 20: 843-847
47 Schmidt F. Göktas O. Jarius S. et al. Olfactory dysfunction in patients with neuromyelitis optica. Mult Scler Int 2013; 2013: 654501
48 Baba T. Nakashima I. Kanbayashi T. et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 2009; 256: 287-288
49 Nakajima H. Fujiki Y. Ito T. et al. Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation. Case Rep Neurol 2011; 3: 263-267
50 Kravljanac R. Martinović V. Dujmović I. et al. Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient. Mult Scler Houndmills Basingstoke Engl 2014; 20: 1404-1406
51 Bradl M. Kanamori Y. Nakashima I. et al. Pain in neuromyelitis optica – prevalence, pathogenesis and therapy. Nat Rev Neurol 2014; 10: 529-536
52 Chanson JB. Zéphir H. Collongues N. et al. Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur J Neurol 2011; 18: 836-841
53 Moore P. Methley A. Pollard C. et al. Cognitive and psychiatric comorbidities in neuromyelitis optica. J Neurol Sci 2016; 360: 4-9
54 Mutch K. Zhao S. Hamid S. et al. Bladder and bowel dysfunction affect quality of life. A cross sectional study of 60 patients with aquaporin-4 antibody positive Neuromyelitis Optica spectrum disorder. Mult Scler Relat Disord 2015; 4: 614-618
55 Zhao S. Mutch K. Elsone L. et al. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler Houndmills Basingstoke Engl 2014; 20: 1658-1661
56 Akaishi T. Nakashima I. Misu T. et al. Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica. J Neuroimmunol 2015; 283: 70-73
57 Zhang N. Li YJ. Fu Y. et al. Cognitive impairment in Chinese neuromyelitis optica. Mult Scler Houndmills Basingstoke Engl 2015; 21: 1839-1846
58 Song Y. Pan L. Fu Y. et al. Sleep abnormality in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation 2015; 2: e94
59 Chavarro V. Mealy MA. Simpson A. et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation 2016; 3: e286 in press
60 Jarius S. Paul F. Franciotta D. et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011; 306: 82-90
61 Majed M. Fryer JP. McKeon A. et al. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. Neurol Neuroimmunol Neuroinflammation 2016; 3: e231
62 Jarius S. Wildemann B. Effect of storage conditions and freeze/thaw cycles on aquaporin-4 antibody (NMO-IgG) serum levels. Clin Chem Lab Med 2011; 49: 2121-2122
63 Jarius S. Franciotta D. Paul F. et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010; 7: 52
64 Jarius S. Franciotta D. Bergamaschi R. et al. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 2010; 48: 659-663
65 Jarius S. Probst C. Borowski K. et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010; 291: 52-56
66 Jarius S. Paul F. Fechner K. et al. Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation 2014; 11: 129
67 Jarius S. Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392
68 Jarius S. Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol Zurich Switz 2013; 23: 661-683
69 Jarius S. Franciotta D. Paul F. et al. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 2012; 320: 32-37
70 Jarius S. Ruprecht K. Kleiter I. et al. MOG-IgG in NMO and related disorders: a multicenter study. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016; 13: 279
71 Reindl M. Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflammation 2015; 2: e60
72 Chalmoukou K. Alexopoulos H. Akrivou S. et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation 2015; 2: e131
73 Waters P. Woodhall M. O’Connor KC. et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflammation 2015; 2: e89
74 Ramanathan S. Prelog K. Barnes EH. et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 2016; 22: 470-482
75 Zamvil SS. Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. Neurol Neuroimmunol Neuroinflammation 2015; 2: e62
76 Kim SM. Woodhall MR. Kim JS. et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation 2015; 2: e163
77 Jarius S. Ruprecht K. Kleiter I. et al. MOG-IgG in NMO and related disorders: a multicenter study. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment, and long-term outcome. J Neuroinflammation 2016; 13: 280
78 Jarius S. Kleiter I. Ruprecht K. et al. MOG-IgG in NMO and related disorders: a multicenter study. Part 3: MOG-IgG-associated brainstem encephalitis. J Neuroinflammation 2016; 13: 281
79 Pache F. Zimmermann H. Mikolajczak J. et al. MOG-IgG in NMO and related disorders: a multicenter study. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016; 13: 282
80 Mader S. Gredler V. Schanda K. et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184
81 Spadaro M. Gerdes LA. Krumbholz M. et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflammation 2016; 3: e257
82 Woodhall M. Çoban A. Waters P. et al. Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci 2013; 335: 221-223
83 Jarius S. Aboul-Enein F. Waters P. et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain J Neurol 2008; 131: 3072-3080
84 Kidd DP. Burton BJ. Graham EM. et al. Optic neuropathy associated with systemic sarcoidosis. Neurol Neuroimmunol Neuroinflammation 2016; 3: e270
85 Jarius S. Paul F. Ruprecht K. et al. Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol 2012; 259: 2743-2745
86 Kimbrough DJ. Mealy MA. Simpson A. et al. Predictors of recurrence following an initial episode of transverse myelitis. Neurol Neuroimmunol Neuroinflammation 2014; 1: e4
87 Jarius S. Franciotta D. Bergamaschi R. et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2008; 79: 1134-1136
88 Pekcevik Y. Mitchell CH. Mealy MA. et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler Houndmills Basingstoke Engl 2016; 22: 302-311
89 Yonezu T. Ito S. Mori M. et al. “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 2014; 20: 331-337
90 Asgari N. Skejoe HPB. Lennon VA. Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient. Neurology 2013; 81: 95-96
91 Flanagan EP. Weinshenker BG. Krecke KN. et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72: 81-87
92 Ventura RE. Kister I. Chung S. et al. Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflammation 2016; 3: e224
93 Ito S. Mori M. Makino T. et al. “Cloud-like enhancement” is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009; 66: 425-428
94 Banker P. Sonni S. Kister I. et al. Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler Houndmills Basingstoke Engl 2012; 18: 1050-1053
95 Sinnecker T. Dörr J. Pfueller CF. et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 2012; 79: 708-714
96 Kister I. Herbert J. Zhou Y. et al. Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica. Mult Scler Int 2013; 2013: 398259
97 Pache F. Zimmermann H. Finke C. et al. Brain parenchymal damage in neuromyelitis optica spectrum disorder – A multimodal MRI study. Eur Radiol 2016; 26: 4413-4422
98 Finke C. Heine J. Pache F. et al. Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. Neurol Neuroimmunol Neuroinflammation 2016; 3: e229
99 Matthews L. Marasco R. Jenkinson M. et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013; 80: 1330-1337
100 Kremer S. Renard F. Achard S. et al. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 2015; 72: 815-822
101 Ringelstein M. Kleiter I. Ayzenberg I. et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler Houndmills Basingstoke Engl 2014; 20: 617-620
102 Brandt AU. Oberwahrenbrock T. Ringelstein M. et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain J Neurol 2011; 134: e193 author reply e194
103 Bock M. Paul F. Dörr J. Diagnosis and monitoring of multiple sclerosis: the value of optical coherence tomography. Nervenarzt 2013; 84: 483-492
104 Bock M. Brandt AU. Kuchenbecker J. et al. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol 2012; 96: 62-67
105 Pfueller CF. Brandt AU. Schubert F. et al. Metabolic changes in the visual cortex are linked to retinal nerve fiber layer thinning in multiple sclerosis. PloS One 2011; 6: e18019
106 Kaufhold F. Zimmermann H. Schneider E. et al. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PloS One 2013; 8: e71145
107 Brandt AU. Oberwahrenbrock T. Kadas EM. et al. Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology 2014; 83: 73-77
108 Schneider E. Zimmermann H. Oberwahrenbrock T. et al. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PloS One 2013; 8: e66151
109 Bennett JL. de Seze J. Lana-Peixoto M. et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler Houndmills Basingstoke Engl 2015; 21: 678-688
110 Petzold A. Wattjes MP. Costello F. et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 2014; 10: 447-458
111 Baumann M. Sahin K. Lechner C. et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015; 86: 265-272
112 Rostasy K. Reindl M. Role of autoantibodies in acquired inflammatory demyelinating diseases of the central nervous system in children. Neuropediatrics 2013; 44: 297-301
113 Flanagan EP. Kaufmann TJ. Krecke KN. et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79: 437-447
114 Trebst C. Raab P. Voss EV. et al. Longitudinal extensive transverse myelitis – it’s not all neuromyelitis optica. Nat Rev Neurol 2011; 7: 688-698
115 Kitley JL. Leite MI. George JS. et al. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler Houndmills Basingstoke Engl 2012; 18: 271-285
116 Iyer A. Elsone L. Appleton R. et al. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014; 47: 154-161
117 Jaiser SR. Winston GP. Copper deficiency myelopathy. J Neurol 2010; 257: 869-881
118 Ringelstein M. Metz I. Ruprecht K. for the Neuromyelitis Optica Study Group (NEMOS). et al. Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler Houndmills Basingstoke Engl 2014; 20: 882-888
119 Ringelstein M. Aktas O. Harmel J. et al. Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis. Nervenarzt 2014; 85: 1298-1303
120 Pröbstel AK. Rudolf G. Dornmair K. et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 2015; 12: 46
121 Galetta SL. Villoslada P. Levin N. et al. Acute optic neuritis: Unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflammation 2015; 2: e135
122 Petzold A. Plant GT. Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev 2014; 13: 539-545
123 Matiello M. Lennon VA. Jacob A. et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70: 2197-2200
124 Jarius S. Frederikson J. Waters P. et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298: 158-162
125 Jarius S. Eichhorn P. Jacobi C. et al. The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?. J Neurol Sci 2009; 280: 98-100
126 Petereit HF. Reske D. Tumani H. et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 2010; 257: 1855-1863
127 Jarius S. Wandinger KP. Borowski K. et al. Antibodies to CV2 / CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 2012; 114: 331-335
128 Mitsdoerffer M. Kuchroo V. Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 2013; 1283: 57-66
129 Jarius S. Paul F. Franciotta D. et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008; 4: 202-214
130 Levy M. Wildemann B. Jarius S. et al. Immunopathogenesis of neuromyelitis optica. Adv Immunol 2014; 121: 213-242
131 Lennon VA. Kryzer TJ. Pittock SJ. et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477
132 Papadopoulos MC. Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013; 14: 265-277
133 Lucchinetti CF. Mandler RN. McGavern D. et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain J Neurol 2002; 125: 1450-1461
134 Misu T. Fujihara K. Kakita A. et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain J Neurol 2007; 130: 1224-1234
135 Roemer SF. Parisi JE. Lennon VA. et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain J Neurol 2007; 130: 1194-1205
136 Sinclair C. Kirk J. Herron B. et al. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol (Berl) 2007; 113: 187-194
137 Saadoun S. Waters P. Bell BA. et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain J Neurol 2010; 133: 349-361
138 Kim W. Lee JE. Li XF. et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler Houndmills Basingstoke Engl 2012; 18: 578-586
139 Chihara N. Aranami T. Sato W. et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011; 108: 3701-3706
140 Takahashi T. Fujihara K. Nakashima I. et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain J Neurol 2007; 130: 1235-1243
141 Bedi GS. Brown AD. Delgado SR. et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler Houndmills Basingstoke Engl 2011; 17: 1225-1230
142 Kim SH. Huh SY. Lee SJ. et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013; 70: 1110-1117
143 Pellkofer HL. Krumbholz M. Berthele A. et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-1315
144 Harmel J. Ringelstein M. Ingwersen J. et al. Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol 2014; 14: 247
145 Araki M. Matsuoka T. Miyamoto K. et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014; 82: 1302-1306
146 Ayzenberg I. Kleiter I. Schröder A. et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70: 394-397
147 Kieseier BC. Stüve O. Dehmel T. et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013; 70: 390-393
148 Ringelstein M. Ayzenberg I. Harmel J. et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 2015; 72: 756-763
149 Khatri BO. Kram J. Dukic M. et al. Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apheresis 2012; 27: 183-192
150 Kim SH. Kim W. Huh SY. et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol Seoul Korea 2013; 9: 36-42
151 Merle H. Olindo S. Jeannin S. et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol Chic Ill 1960 2012; 130: 858-862
152 Watanabe S. Nakashima I. Misu T. et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler Houndmills Basingstoke Engl 2007; 13: 128-132
153 Bonnan M. Valentino R. Olindo S. et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler Houndmills Basingstoke Engl 2009; 15: 487-492
154 Matiello M. Schaefer-Klein J. Sun D. et al. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 2013; 70: 1118-1125
155 Isobe N. Yonekawa T. Matsushita T. et al. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Mult Scler Houndmills Basingstoke Engl 2012; 18: 1541-1551
156 Jarius S. Jacob S. Leite M. et al. NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro. London: Sage publication Ltd; 2007: S159-S159
157 Kalluri SR. Illes Z. Srivastava R. et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010; 67: 1201-1208
158 Misu T. Höftberger R. Fujihara K. et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (Berl) 2013; 125: 815-827
159 Kuroda H. Fujihara K. Takano R. et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 2013; 254: 178-182
160 Pittock SJ. Lennon VA. McKeon A. et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12: 554-562
161 Paul F. Hope for a rare disease: eculizumab in neuromyelitis optica. Lancet Neurol 2013; 12: 529-531
162 Quan C. Yu H. Qiao J. et al. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 2013; 19: 289-298
163 Quan C. ZhangBao J. Lu J. et al. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol 2015; 282: 45-53
164 Wang H. Wang K. Zhong X. et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 2012; 32: 1007-1011
165 Vaknin-Dembinsky A. Brill L. Orpaz N. et al. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult Scler Houndmills Basingstoke Engl 2010; 16: 1453-1457
166 Takeshita Y. Obermeier B. Cotleur AC. et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflammation 2017; 4: e311
167 Ratelade J. Bennett JL. Verkman AS. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem 2011; 286: 45156-45164
168 Hinson SR. Roemer SF. Lucchinetti CF. et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205: 2473-2481
169 Alberdi E. Sánchez-Gómez MV. Torre I. et al. Activation of kainate receptors sensitizes oligodendrocytes to complement attack. J Neurosci Off J Soc Neurosci 2006; 26: 3220-3228
170 Titulaer MJ. Höftberger R. Iizuka T. et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-428
171 Zeka B. Hastermann M. Hochmeister S. et al. Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathol (Berl) 2015; 130: 783-798
172 Hertwig L. Pache F. Romero-Suarez S. et al. Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Mult Scler Houndmills Basingstoke Engl 2016; 22: 160-173
173 Hiepe F. Dörner T. Hauser AE. et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011; 7: 170-178
174 Collongues N. de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 2011; 4: 111-121
175 Sellner J. Boggild M. Clanet M. et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol Off J Eur Fed Neurol Soc 2010; 17: 1019-1032
176 Kimbrough DJ. Fujihara K. Jacob A. et al. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord 2012; 1: 180-187
177 Trebst C. Berthele A. Jarius S. Neuromyelitis optica Studiengruppe (NEMOS). et al. Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group. Nervenarzt 2011; 82: 768-777
178 Kleiter I. Gold R. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurother J Am Soc Exp Neurother 2016; 13: 70-83
179 Wingerchuk DM. Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008; 10: 55-66
180 Yamasaki R. Matsushita T. Fukazawa T. et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler Houndmills Basingstoke Engl 2016; 22: 1337-1348
181 Papadopoulos MC. Bennett JL. Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 2014; 10: 493-506
182 Abboud H. Petrak A. Mealy M. et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler Houndmills Basingstoke Engl 2016; 22: 185-192
183 Bonnan M. Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012; 2012: 787630
184 Kleiter I. Gahlen A. Borisow N. Neuromyelitis Optica Study Group. et al. Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 2016; 79: 206-216
185 Kleiter I. Hellwig K. Berthele A. Neuromyelitis Optica Study Group. et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239-245
186 Jacob A. Hutchinson M. Elsone L. et al. Does natalizumab therapy worsen neuromyelitis optica?. Neurology 2012; 79: 1065-1066
187 Kitley J. Evangelou N. Küker W. et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci 2014; 339: 223-225
188 Ayzenberg I. Schöllhammer J. Hoepner R. Neuromyelitis Optica Study Group (NEMOS). et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol 2016; 263: 575-582
189 Min JH. Kim BJ. Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler Houndmills Basingstoke Engl 2012; 18: 113-115
190 Azzopardi L. Cox AL. McCarthy CL. et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 2016; 263: 25-29
191 Kim SH. Huh SY. Kim W. et al. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?. Mult Scler Houndmills Basingstoke Engl 2013; 19: 1493-1498
192 Carroll WM. Saida T. Kim HJ. Pam-Asian Committee on Treatment and Research of Multiple Sclerosis. et al. A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica). Mult Scler Houndmills Basingstoke Engl 2013; 19: 1371-1380
193 Jarernsook B. Siritho S. Prayoonwiwat N. Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases. Mult Scler Houndmills Basingstoke Engl 2013; 19: 585-592
194 Kornberg MD. Newsome SD. Unmasking and provoking severe disease activity in a patient with NMO spectrum disorder. Neurol Neuroimmunol Neuroinflammation 2015; 2: e66
195 Elsone L. Kitley J. Luppe S. et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler Houndmills Basingstoke Engl 2014; 20: 1533-1540
196 Costanzi C. Matiello M. Lucchinetti CF. et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77: 659-666
197 Mealy MA. Wingerchuk DM. Palace J. et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014; 71: 324-330
198 Jeong IH. Park B. Kim SH. et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler Houndmills Basingstoke Engl 2016; 22: 329-339
199 Torres J. Pruitt A. Balcer L. et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015; 351: 31-35
200 Nakashima I. Takahashi T. Cree BAC. et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci Off J Neurosurg Soc Australas 2011; 18: 997-998
201 Perumal JS. Kister I. Howard J. et al. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflammation 2015; 2: e61
202 Radaelli M. Moiola L. Sangalli F. et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler Houndmills Basingstoke Engl 2016; 22: 511-519
203 Jacob A. Matiello M. Weinshenker BG. et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128-1133
204 Huh SY. Kim SH. Hyun JW. et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014; 71: 1372-1378
205 Neff RT. Hurst FP. Falta EM. et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86: 1474-1478
206 Içöz S. Tüzün E. Kürtüncü M. et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010; 120: 71-75
207 Viswanathan S. Wong AHY. Quek AML. et al. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol 2015; 282: 92-96
208 Elsone L. Panicker J. Mutch K. et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler Houndmills Basingstoke Engl 2014; 20: 501-504
209 Dörr J. Bitsch A. Schmailzl KJG. et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2009; 73: 991-993
210 Paul F. Dörr J. Würfel J. et al. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007; 78: 198-200
211 Stroet A. Hemmelmann C. Starck M. et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord 2012; 5: 75-79
212 Buttmann M. Seuffert L. Mäder U. et al. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. Neurology 2016; 86: 2203-2207
213 Chanvillard C. Millward JM. Lozano M. et al. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PloS One 2012; 7: e39625
214 Kim SH. Kim W. Park MS. et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68: 473-479
215 Cabre P. Olindo S. Marignier R. Aegis of French National Observatory of Multiple Sclerosis. et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013; 84: 511-516
216 Weinstock-Guttman B. Ramanathan M. Lincoff N. et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006; 63: 957-963
217 Kitley J. Elsone L. George J. et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013; 84: 918-921
218 Ramanathan RS. Malhotra K. Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol 2014; 14: 51
219 Minagar A. Sheremata WA. Treatment of Devic’s Disease with Methotrexate and Prednisone. Int J MS Care 2000; 2: 43-49
220 Kageyama T. Komori M. Miyamoto K. et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013; 260: 627-634
221 Tanaka M. Kinoshita M. Tanaka K. Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders. Mult Scler Houndmills Basingstoke Engl 2015; 21: 669
222 Bichuetti DB. Oliveira EML. Boulos F de C. et al. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 2012; 69: 938-939
223 Cree BA. Bennett JL. Sheehan M. et al. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler Houndmills Basingstoke Engl 2016; 22: 862-872
224 Verkman AS. Phuan PW. Asavapanumas N. et al. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol Zurich Switz 2013; 23: 684-695
225 Mealy MA. Shin K. John G. et al. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol 2015; 6: 413-418
226 Levy M. Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflammation 2014; 1: e5
227 Bourre B. Marignier R. Zéphir H. NOMADMUS Study Group. et al. Neuromyelitis optica and pregnancy. Neurology 2012; 78: 875-879
228 Fragoso YD. Adoni T. Bichuetti DB. et al. Neuromyelitis optica and pregnancy. J Neurol 2013; 260: 2614-2619
229 Reuss R. Rommer PS. Brück W. et al. A woman with acute myelopathy in pregnancy: case outcome. BMJ 2009; 339: b4026
230 Nour MM. Nakashima I. Coutinho E. et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology 2016; 86: 79-87
231 Saadoun S. Waters P. Leite MI. et al. Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol Baltim Md 1950 2013; 191: 2999-3005
232 Davoudi V. Keyhanian K. Bove RM. et al. Immunology of neuromyelitis optica during pregnancy. Neurol Neuroimmunol Neuroinflammation 2016; 3: e288
233 Shimizu Y. Fujihara K. Ohashi T. et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler Houndmills Basingstoke Engl 2016; 22: 1413-1420
234 Greer IA. Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407
235 Keeling D. Mackie I. Moore GW. British Committee for Standards in Haematology. et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47-58
236 Empson M. Lassere M. Craig J. et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005; CD002859
237 Pellkofer HL. Suessmair C. Schulze A. et al. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler Houndmills Basingstoke Engl 2009; 15: 1006-1008
238 Ringelstein M. Harmel J. Distelmaier F. et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler Houndmills Basingstoke Engl 2013; 19: 1544-1547
239 Collongues N. Marignier R. Jacob A. et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler Houndmills Basingstoke Engl 2013; 20: 1086-1094
240 Tillema JM. McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J Child Neurol 2012; 27: 1437-1447
241 Wandinger KP. Stangel M. Witte T. et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren’s syndrome. Arthritis Rheum 2010; 62: 1198-1200
242 Závada J. Nytrová P. Wandinger KP. et al. Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int 2013; 33: 259-263
243 Carvalho DC. Tironi TS. Freitas DS. et al. Sjögren syndrome and neuromyelitis optica spectrum disorder co-exist in a common autoimmune milieu. Arq Neuropsiquiatr 2014; 72: 619-624
244 Jayarangaiah A. Sehgal R. Epperla N. Sjögren’s syndrome and neuromyelitis optica spectrum disorders (NMOSD) – a case report and review of literature. BMC Neurol 2014; 14: 200
245 Kolfenbach JR. Horner BJ. Ferucci ED. et al. Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res 2011; 63: 1203-1208
246 Bergamaschi R. Jarius S. Robotti M. et al. Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol 2009; 256: 2097-2099
247 Jarius S. Jacob S. Waters P. et al. Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. J Neurol Neurosurg Psychiatry 2008; 79: 1084
248 Pittock SJ. Lennon VA. de Seze J. et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65: 78-83
249 Komai T. Shoda H. Yamaguchi K. et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Mod Rheumatol Jpn Rheum Assoc 2016; 26: 294-296
250 Ramanathan S. Reddel SW. Henderson A. et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation 2014; 1: e40
251 Hacohen Y. Absoud M. Deiva K. et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflammation 2015; 2: e81
252 Kitley J. Waters P. Woodhall M. et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-283
253 Höftberger R. Sepulveda M. Armangue T. et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler Houndmills Basingstoke Engl 2015; 21: 866-874
254 Di Pauli F. Höftberger R. Reindl M. et al. Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflammation 2015; 2: e175
255 Jarius S. Eichhorn P. Franciotta D. et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol 2016;

Zusatzmaterial

Literatur